Kim, Soyeon https://orcid.org/0000-0002-2798-2257
Ko, Hyunwoong https://orcid.org/0000-0001-7135-3872
Myung, Woojae https://orcid.org/0000-0001-9985-2032
Yoon, Joohyun https://orcid.org/0000-0002-5350-9623
Kim, Kiwon
Jung, Sang-Hyuk https://orcid.org/0000-0003-4116-3327
Shim, Injeong https://orcid.org/0000-0002-1001-0945
Cha, Soojin
Kim, Beomsu
Kang, Jae Myeong
Park, Woong-Yang
Natarajan, Pradeep
Do, Ron https://orcid.org/0000-0002-3144-3627
Won, Hong-Hee https://orcid.org/0000-0001-5719-0552
Funding for this research was provided by:
National Research Foundation of Korea (NRF-2022R1A2C2009998)
National Research Foundation of Korea (NRF-2022R1A2C2009998)
National Research Foundation of Korea (NRF-2022R1A6A3A01087659)
National Research Foundation of Korea (NRF-2021R1A2C4001779)
Korea Health Industry Development Institute (HI19C1328000020)
Korea Health Industry Development Institute (HI19C1328000020)
Article History
Received: 15 December 2023
Accepted: 1 November 2024
First Online: 2 January 2025
Competing interests
: All authors completed the International Committee of Medical Journal Editors uniform disclosure form at (available as Supplementary Table ) and declare the following: W.-Y.P. is employed by a commercial company, GENINUS. P.N. reports investigator-initiated grants from Amgen, Apple, AstraZeneca, Boston Scientific and Novartis and personal fees from Apple, AstraZeneca, Blackstone Life Sciences, Foresite Labs, Novartis and Roche/Genentech. P.N. is also a co-founder of TenSixteen Bio and a scientific advisory board member of Esperion Therapeutics, geneXwell and TenSixteen Bio and reports spousal employment at Vertex, all unrelated to the present work. R.D. reports receiving grants from AstraZeneca and grants and non-financial support from Goldfinch Bio; being a scientific co-founder, consultant and equity holder at Pensieve Health; and being a consultant for Variant Bio, all unrelated to this work. All other authors declare no competing interests.